Ambrx Biopharma Operating Income

Ambrx Biopharma (AMAM) currently reports a operating income of $-69M as of September 2023. That compares with $-73M in the prior-year period — up 4.8% year over year. Use the charts on this page to explore Ambrx Biopharma's operating income history and peer comparisons.

Ambrx Biopharma's operating income increased from $-73M to $-69M — a 4.8% year-over-year increase (period ending September 2023). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Ambrx Biopharma reported $-69M in operating income as of September 2023. That compares with $-73M in the prior-year period — up 4.8% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current operating income of $-69M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Ambrx Biopharma, and consider following AMAM for alerts when major investors trade the stock.

Ambrx Biopharma is classified in the Healthcare sector. On operating income, it currently shows $-69M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing AMAM with unrelated industries.